


I20 ALBANY STREET • TOWER ONE, SUITE 505 • NEW BRUNSWICK, NJ 08901 • TEL: 732.729.9619 • FAX: 732.729.9625 • WWW.HINJ.ORG

April 9, 2013

Hon. Glenn A. Grant, J.A.D Acting Administrative Director of the Courts Rules Comments Hughes Justice Complex, P.O. Box 037 Trenton, New Jersey 08625-0037



Re: Proposed Amendments to N.J.R.E. 702

Dear Judge Grant:

On behalf of the HealthCare Institute of New Jersey ("HINJ"), I write in support of the adoption of amendments to New Jersey Rule of Evidence ("N.J.R.E.") 702 governing the admissibility of expert testimony proposed to the Supreme Court by the New Jersey Civil Justice Institute ("NJCJI") by letter dated April 9, 2015.

As an organization representing research-based biopharmaceutical and medical technology companies with a presence in New Jersey, we agree with NJCJI that the standards governing the admissibility of expert testimony in New Jersey civil litigation should be clear, predictable and consistent for all litigants. For the reasons expressed in NJCJI's letter, we believe this outcome would be enhanced by New Jersey's adoption of the standard reflected in Federal Rule of Evidence 702, which represents the best-defined, best-established body of case law on the subject in the country at this time, as reflected by the fact that it is currently utilized in numerous jurisdictions.

We therefore join NJCJI in supporting the adoption of amendments to N.J.R.E. 702 that would bring it into alignment with current Federal Rule of Evidence 702.

Thank you for affording me the opportunity to comment.

Respectfully submitted,

Dean J. Paranicas

President and Chief Executive Officer